Gracell Biotechnologies (Shanghai) Co., Ltd.
3 clinical trials · Sponsor
◉ Watch Gracell Biotechnologies (Shanghai) Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis (NCT07250269) | Gracell Biotechnologies (Shanghai) Co., Ltd. | 2025-10-29 |
| A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus (NCT06530849) | Gracell Biotechnologies (Shanghai) Co., Ltd. | 2024-08-22 |
| A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma (NCT06235229) | Gracell Biotechnologies (Shanghai) Co., Ltd. | 2023-12-26 |
Track Gracell Biotechnologies (Shanghai) Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.